



Vaccine Fact Sheet

MenACWY (MCV4)

Brand Name Menactra®
Manufacturer Sanofi Pasteur
Abbreviation MenACWY-D

Menveo®
Novartis
MenACWY-CRM

Protects Against Invasive Meningococcal Disease caused by *Neisseria meningitidis* A, C, Y and W-135

Invasive Meningococcal Disease caused by *Neisseria meningitidis* A, C, Y and W-135

Routine Schedule One (1) dose at 11-12 years and one (1) booster dose at 16 years

One (1) dose at 11-12 years and one (1) booster dose at 16 years

Minimum Intervals 8 week minimum interval between doses

8 week minimum interval between doses

Approved for use in Persons aged 9 months through 55 years

Persons aged 2 months through 55 years

Administration Intramuscular (IM) injection

Intramuscular (IM) injection

Packaging Vaccine is packaged as 5 single-dose 0.5mL vials

Vaccine is packaged as 5 single-dose 0.5mL vials of Men CYW-135 liquid component and 5 single-dose vials of lyophilized Men A component.

Storage Refrigerate between 36°F and 46°F (2°C to 8°C)
DO NOT FREEZE

Refrigerate between 36°F and 46°F (2°C to 8°C)
PROTECT VACCINE FROM LIGHT
DO NOT FREEZE

Full ACIP Recommendations <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/ mening.html>

<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/ mening.html>

VFC Letter http://eziz.org/assets/docs/vfcletter_2011_11_MCV4.pdf

http://eziz.org/assets/docs/vfcletter_2011_11_MCV4.pdf

Billing Codes* CHDP code: 69
CPT code for vaccine: 90734
CPT code for administration: 90460
Medi-Cal Fee-For-Service (FFS) administration: 90734 with modifiers –SK (high-risk) and –SL (VFC)
ICD-10-CM code (encounter for immunization): Z23
*<http://www.aafp.org/practice-management/payment/coding/admin.html>

CHDP code: 69
CPT code for vaccine: 90734
CPT code for administration: 90460
Medi-Cal Fee-For-Service (FFS) administration: 90734 with modifiers –SK (high-risk) and –SL (VFC)
ICD-10-CM code (encounter for immunization): Z23
*<http://www.aafp.org/practice-management/payment/coding/admin.html>

- Comments**
- Licensed in 2005
 - Boosters are recommended for those who remain at high risk. See ACIP recommendations.
 - Does not protect against Meningococcal serogroup B
 - For routine recommendations, refer to [Meningococcal Vaccines—Routine Risk](#)
 - For recommendations for high-risk patients, refer to [Meningococcal Vaccines—High Risk Populations](#)
 - If Menactra is given to children with HIV infection or asplenia (including sickle cell disease), complete the PCV13 series and wait at least age 2 years before giving Menactra. See ACIP recommendations. These restrictions do not apply to Menveo.
 - It is recommended that Menactra be given either before, or concomitantly with, the next recommended dose of DTaP vaccine.

- Licensed in 2010
- Boosters are recommended for those who remain at high risk. See ACIP recommendations.
- Does not protect against Meningococcal serogroup B
- For routine recommendations, refer to [Meningococcal Vaccines—Routine Risk](#)
- For recommendations for high-risk patients, refer to [Meningococcal Vaccines—High Risk Populations](#)
- Use only supplied (CWY) liquid component to reconstitute freeze dried component (A)
- MenCWY and Men A vials have separate lot numbers; record the lot numbers from the box